Chimeric Therapeutics (CHM) H2 2025 earnings summary

Executive summary

• Achieved significant clinical milestones in CDH17 and CORE-NK trials, including first dose level completion and patient responses in AML studies.

• Strengthened leadership with new CEO and board appointment, enhancing clinical and scientific capabilities.

• Advanced three key cell therapy programs targeting high unmet needs in oncology.

Financial highlights

• Reported net loss of $10.4 million for FY25, down from $12.5 million in FY24, reflecting reduced headcount and lower admin expenses.

• Revenue from ordinary activities was $3.97 million, primarily from non-dilutive funding.

• Cash reserves increased to $5.76 million (FY24: $3.05 million) due to placements, entitlement offer, and R&D tax rebate.

• Net assets at year-end were $1.97 million (FY24: $2.47 million).

Outlook and guidance

• Focus remains on advancing clinical development plans and maintaining momentum across programs.

• No short-term revenue expected from development programs; long-term value creation anticipated upon successful outcomes.